Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 02, 2015 4:38 AM ET

Pharmaceuticals

Company Overview of Actelion Pharmaceuticals Ltd

Company Overview

Actelion Pharmaceuticals Ltd. provides drug discovery and development services. The company develops drugs for pulmonary arterial hypertension treatments that cover the spectrum of diseases ranging from WHO functional class (FC) II through to FC IV, with oral, inhaled, and intravenous medications. It also provides Tracleer, an endothelin receptor antagonist; Veletri (epoprostenol for injection), an intravenous prostacyclin; Ventavis, an inhaled formulation of iloprost; Valchlor (mechlorethamine) gel that is to be applied topically once-a-day and dries on the skin; and ZAVESCA (Miglustat), an oral molecule for the treatment of type 1 Gaucher disease. The company was founded in 1997 and is hea...

Gewerbestrasse 16

Allschwil,  4123

Switzerland

Founded in 1997

Phone:

41 61 565 65 65

Fax:

41 61 565 65 00

Key Executives for Actelion Pharmaceuticals Ltd

Actelion Pharmaceuticals Ltd does not have any Key Executives recorded.

Actelion Pharmaceuticals Ltd Key Developments

Actelion Pharmaceuticals Ltd Presents at Berenberg European Conference USA 2015, May-19-2015

Actelion Pharmaceuticals Ltd Presents at Berenberg European Conference USA 2015, May-19-2015 . Venue: Tarrytown House Estate, 49 East Sunnyside Lane, Tarrytown, NY 10591, United States. Speakers: Andrew Weiss, SVP, IR & Corporate Affairs.

Actelion Pharmaceuticals Ltd, Annual General Meeting, May 08, 2015

Actelion Pharmaceuticals Ltd, Annual General Meeting, May 08, 2015.

Gour Medical SA Enters into a Definitive Worldwide License Agreement with Actelion Pharmaceuticals Ltd

Gour Medical SA announced that it has entered into a definitive worldwide license agreement with Actelion Pharmaceuticals Ltd. for the veterinary development of one of Actelion’s early-stage clinical dual orexin receptor antagonists, which the company had decided not to pursue further. Under the terms of the agreement Actelion will receive an upfront payment and will be eligible to receive further payments subject to potential development and regulatory milestones, as well as royalties on sales if the compound is commercialized.

Similar Private Companies By Industry

Company Name Region
Vifor Pharma Ltd. Europe
TRB Chemedica International SA Europe
Helsinn Healthcare S.A. Europe
Albea Pharmaceuticals AG Europe
ADD Advanced Drug Delivery Technologies AG Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
March 10, 2015
Actelion Pharmaceuticals Ltd, Worldwide Rights to A Dual Orexin Receptor Antagonist
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Actelion Pharmaceuticals Ltd, please visit www.actelion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.